Research programme: YSTOP anticancer therapeutics - Y's TherapeuticsAlternative Names: YSTOP
Latest Information Update: 23 Sep 2009
At a glance
- Originator Ys Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jul 2005 This programme is still in active development
- 09 Jul 2004 Preclinical trials in Cancer in Japan (unspecified route)